SIHUAN PHARM: Notification Letter and Request Form to Non-registered Holder
SIHUAN PHARM: Notification Letter and Change Request Form to Registered Shareholder
SIHUAN PHARM: FORM OF PROXY FOR USE AT ANNUAL GENERAL MEETING
SIHUAN PHARM: ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT 2023
SIHUAN PHARM: VOLUNTARY ANNOUNCEMENT-THREE PRODUCTS OF THE INSULIN ASPART SERIES DEVELOPED BY HUISHENG BIOPHARMACEUTICAL OBTAINED BID-WINNING QUALIFICATION IN THE SPECIALISING RENEWAL IN INSULIN PROCUREMENT
SIHUAN PHARM: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2024
SIHUAN PHARM: VOLUNTARY ANNOUNCEMENT-SIHUAN PHARMACEUTICAL OBTAINED CLASS III MEDICAL DEVICE REGISTRATION CERTIFICATE FROM NMPA FOR EXCLUSIVELY DISTRIBUTED DUAL WAVE RF TREATMENT DEVICE SYLFIRM X
SIHUAN PHARM: Monthly Return of Equity Issuer on Movements in Securities for the month ended 29 February 2024
SIHUAN PHARM: VOLUNTARY ANNOUNCEMENT - PARTICIPATION IN THE CONSORTIUM WHO WAS SELECTED AS THE PRE-RESTRUCTURING INVESTOR FOR THE BANKRUPTCY AND RESTRUCTURING PROJECT OF JI YAO HOLDING
SIHUAN PHARM: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2024
SIHUAN PHARM: VOLUNTARY ANNOUNCEMENT-HUISHENG BIOPHARMACEUTICAL''S SGLT-2 INHIBITOR INNOVATIVE DRUG PROLINE JANAGLIFLOZIN TABLETS OBTAINED DRUG REGISTRATION APPROVAL FROM NMPA
SIHUAN PHARM: VOLUNTARY ANNOUNCEMENT - FOUR NON-PVC SOLID-LIQUID DOUBLE CHAMBER BAG PRODUCTS, DEVELOPED BY SIHUAN PHARMACEUTICAL''S ASSOCIATE COMPANY BEIJING RUIYE, ARE NEWLY INCLUDED IN NRDL 2023
SIHUAN PHARM: VOLUNTARY ANNOUNCEMENT-THREE INSULIN ASPART PRODUCTS DEVELOPED BY HUISHENG BIOPHARMACEUTICAL OBTAINED DRUG REGISTRATION APPROVAL FROM NMPA
SIHUAN PHARM: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2023
SIHUAN PHARM: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2023
SIHUAN PHARM: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2023
SIHUAN PHARM: VOLUNTARY ANNOUNCEMENT - IND APPLICATION OF INSULIN DEGLUDEC AND LIRAGLUTIDE INJECTION, DEVELOPED BY HUISHENG BIOPHARMACEUTICAL, APPROVED BY NMPA
SIHUAN PHARM: VOLUNTARY ANNOUNCEMENT - THE NDA OF CLASS 1 INNOVATIVE DRUG BIROCICLIB''S MONOTHERAPY, INDEPENDENTLY DEVELOPED BY XUANZHU BIOPHARM FOR THE TREATMENT OF ADVANCED BREAST CANCER, WAS ACCEPTED BY NMPA
SIHUAN PHARM: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2023
SIHUAN PHARM: Notification Letter and Request Form to Non-registered Holder
No Data